Illumina Inc

NASDAQ:ILMNUnited States

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The Company's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.

Contact Information

Headquarters

5200 Illumina WaySAN DIEGO, CA, United States 92122-4616

Phone

858-202-4500

Fax

858-202-4766

Executives

Independent Chairman of the Board

John Thompson

President, Chief Executive Officer, Director

Francis deSouza

Chief Financial Officer

Sam Samad

Chief People Officer

Aimee Hoyt

Chief Technology Officer, Head of Research and Product Development

Alex Aravanis